Form 4 holding
10%+ Owner
RayzeBio, Inc.
- Security class
- Common Stock
- Shares / value
- 1,857,706
- Estimated value
- $116,106,625
- Report date
- 19 Sep 2023
- Price
- $62.50
- Ownership
- Indirect
Redmile Group, LLC
Insider Reports History
- Reporting-owner location
- Larkspur, CA
- Latest reporting-owner signature
-
By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Redmile Group, LLC
Form 4 holding
10%+ Owner
ADC Therapeutics SA
- Security class
- Common Stock
- Shares / value
- 12,666,731
- Estimated value
- $41,534,210
- Report date
- 02 Apr 2026
- Price
- $3.28
- Ownership
- Indirect
Form 4 holding
Director
Absci Corp
- Security class
- Common Stock
- Shares / value
- 8,262,136
- Estimated value
- $41,142,959
- Report date
- 12 Jun 2024
- Price
- $4.98
- Ownership
- Indirect
Form 4 holding
10%+ Owner
ADC Therapeutics SA
- Security class
- Common Stock
- Shares / value
- 10,265,297
- Estimated value
- $33,659,908
- Report date
- 02 Apr 2026
- Price
- $3.28
- Ownership
- Direct
Form 4 holding
10%+ Owner
Entrada Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 1,954,420
- Estimated value
- $31,251,176
- Report date
- 02 Nov 2021
- Price
- $15.99
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Zymeworks Inc.
- Security class
- Common Stock, par value $0.00001 per share
- Shares / value
- 6,075,918
- Estimated value
- $30,584,956
- Report date
- 13 Oct 2022
- Price
- $5.03
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
FATE THERAPEUTICS INC
- Security class
- Class A Convertible Preferred Stock
- Shares / value
- 2,755,086
- Estimated value
- $23,142,722
- Report date
- 20 Apr 2026
- Price
- $8.40
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Verve Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 1,936,530
- Estimated value
- $19,365,300
- Report date
- 21 Jun 2021
- Price
- $10.00
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
FATE THERAPEUTICS INC
- Security class
- Common Stock
- Shares / value
- 12,884,277
- Estimated value
- $15,461,132
- Report date
- 20 Apr 2026
- Price
- $1.20
- Ownership
- Indirect
Form 4 holding
10%+ Owner
ADC Therapeutics SA
- Security class
- Pre-Funded Warrants
- Shares / value
- 3,846,153
- Estimated value
- $14,999,996
- Report date
- 27 Oct 2025
- Price
- $3.90
- Ownership
- Direct
- Underlying class
- Common Share
- Underlying amount
Form 4 holding
10%+ Owner
ADC Therapeutics SA
- Security class
- Pre-Funded Warrants
- Shares / value
- 3,846,153
- Estimated value
- $14,999,996
- Report date
- 27 Oct 2025
- Price
- $3.90
- Ownership
- Indirect
- Underlying class
- Common Share
- Underlying amount
Form 4 holding
10%+ Owner
Adagio Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 3,390,960
- Estimated value
- $13,394,292
- Report date
- 10 Aug 2021
- Price
- $3.95
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Shattuck Labs, Inc.
- Security class
- Common Stock, par value $0.0001 per share
- Shares / value
- 5,539,724
- Estimated value
- $6,924,655
- Report date
- 04 Dec 2024
- Price
- $1.25
- Ownership
- Indirect
Form 4 holding
Director
Atara Biotherapeutics, Inc.
- Security class
- Common Stock, par value $0.0001 per share
- Shares / value
- 441,701
- Estimated value
- $3,356,927
- Report date
- 16 May 2025
- Price
- $7.60
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
FATE THERAPEUTICS INC
- Security class
- Cash-settled Swaps
- Shares / value
- 502,769
- Estimated value
- $844,652
- Report date
- 20 Apr 2026
- Price
- $1.68
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
FATE THERAPEUTICS INC
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 87,900
- Estimated value
- $109,200
- Report date
- 12 Jun 2026
- Price
- $2.73
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Augmedix, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 02 Oct 2024
- Price
- $2.35
- Ownership
- Direct
Form 4 holding
Director, 10%+ Owner
Augmedix, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 02 Oct 2024
- Price
- $2.35
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
FATE THERAPEUTICS INC
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 20 Apr 2026
- Price
- $1.20
- Ownership
- Direct
Form 4 holding
Director, 10%+ Owner
IGM Biosciences, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 14 Aug 2025
- Price
- $1.33
- Ownership
- Indirect
Form 4 holding
Former 10% Owner and Director
Science 37 Holdings, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 12 Mar 2024
- Price
- $5.75
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
MedAvail Holdings, Inc.
- Security class
- Series A Warrants to Purchase Common Stock
- Shares / value
- 38,916,562
- Estimated value
- Report date
- 16 Jun 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
MedAvail Holdings, Inc.
- Security class
- Series A Warrants to Purchase Common Stock
- Shares / value
- 38,916,562
- Estimated value
- Report date
- 16 Jun 2023
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Shattuck Labs, Inc.
- Security class
- Pre-Funded Warrants to Purchase Common Stock
- Shares / value
- 7,198,553
- Estimated value
- Report date
- 25 Aug 2025
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Shattuck Labs, Inc.
- Security class
- Common Warrants to Purchase Common Stock
- Shares / value
- 4,097,730
- Estimated value
- Report date
- 25 Aug 2025
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
FATE THERAPEUTICS INC
- Security class
- Pre-Funded Warrants to Purchase Common Stock
- Shares / value
- 3,893,674
- Estimated value
- Report date
- 20 Apr 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Augmedix, Inc.
- Security class
- Breakeven Warrant
- Shares / value
- 1,093,799
- Estimated value
- Report date
- 20 Nov 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Augmedix, Inc.
- Security class
- Breakeven Warrant
- Shares / value
- 1,093,799
- Estimated value
- Report date
- 20 Nov 2023
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Absci Corp
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 36,274
- Estimated value
- Report date
- 12 Jun 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Shattuck Labs, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 33,150
- Estimated value
- Report date
- 14 Jul 2025
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Adagio Therapeutics, Inc.
- Security class
- Series C Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 10 Aug 2021
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Augmedix, Inc.
- Security class
- Breakeven Warrants
- Shares / value
- 0
- Estimated value
- Report date
- 02 Oct 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Augmedix, Inc.
- Security class
- Breakeven Warrants
- Shares / value
- 0
- Estimated value
- Report date
- 02 Oct 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Augmedix, Inc.
- Security class
- Pre-Funded Warrants to Purchase Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 02 Oct 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Augmedix, Inc.
- Security class
- Pre-Funded Warrants to Purchase Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 02 Oct 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Entrada Therapeutics, Inc.
- Security class
- Series B Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 02 Nov 2021
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
FATE THERAPEUTICS INC
- Security class
- Cash-settled Swaps
- Shares / value
- 0
- Estimated value
- Report date
- 20 Apr 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
FATE THERAPEUTICS INC
- Security class
- Class A Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 20 Apr 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
FATE THERAPEUTICS INC
- Security class
- Pre-Funded Warrants to Purchase Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 20 Apr 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
IGM Biosciences, Inc.
- Security class
- Pre-Funded Warrants to Purchase Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 14 Aug 2025
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
RayzeBio, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 19 Sep 2023
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
RayzeBio, Inc.
- Security class
- Series C Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 19 Sep 2023
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
RayzeBio, Inc.
- Security class
- Series D Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 19 Sep 2023
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Former 10% Owner and Director
Science 37 Holdings, Inc.
- Security class
- Earn-Out Right
- Shares / value
- 0
- Estimated value
- Report date
- 12 Mar 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Former 10% Owner and Director
Science 37 Holdings, Inc.
- Security class
- Stock Options (Right to Buy)
- Shares / value
- 0
- Estimated value
- Report date
- 12 Mar 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Verve Therapeutics, Inc.
- Security class
- Series B Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 21 Jun 2021
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Redmile Group, LLC
4
FATE
FATE THERAPEUTICS INC
- Report period
- 12 Jun 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 15 Jun 2026, 17:16
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4/A
FATE
FATE THERAPEUTICS INC
- Report period
- 20 Apr 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 23 Apr 2026, 21:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ADCT
ADC Therapeutics SA
- Report period
- 31 Mar 2026
- Transactions
- 6
- Transaction value
- -$19,636,340
- Accepted by SEC
- 02 Apr 2026, 21:00
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ADCT
ADC Therapeutics SA
- Report period
- 27 Oct 2025
- Transactions
- 2
- Transaction value
- +$29,999,993
- Accepted by SEC
- 28 Oct 2025, 21:00
- Role
- 10%+ Owner
- Next action
- Open filing details
4
STTK
Shattuck Labs, Inc.
- Report period
- 25 Aug 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 26 Aug 2025, 17:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 14 Aug 2025
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 15 Aug 2025, 17:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
STTK
Shattuck Labs, Inc.
- Report period
- 14 Jul 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 16 Jul 2025, 21:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 30 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2025, 16:01
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ADCT
ADC Therapeutics SA
- Report period
- 11 Jun 2025
- Transactions
- 2
- Transaction value
- +$96,780,687
- Accepted by SEC
- 13 Jun 2025, 18:00
- Role
- 10%+ Owner
- Next action
- Open filing details
4
FATE
FATE THERAPEUTICS INC
- Report period
- 29 May 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 30 May 2025, 18:54
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 16 May 2025
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 23 May 2025, 16:01
- Role
- Director
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 31 Mar 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 02 Apr 2025, 21:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 31 Dec 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 02 Jan 2025, 21:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
FATE
FATE THERAPEUTICS INC
- Report period
- 20 Dec 2024
- Transactions
- 7
- Transaction value
- $0
- Accepted by SEC
- 26 Dec 2024, 21:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
FATE
FATE THERAPEUTICS INC
- Report period
- 12 Dec 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 16 Dec 2024, 21:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ADCT
ADC Therapeutics SA
- Report period
- 11 Dec 2024
- Transactions
- 4
- Transaction value
- +$609,000
- Accepted by SEC
- 13 Dec 2024, 21:00
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ADCT
ADC Therapeutics SA
- Report period
- 04 Dec 2024
- Transactions
- 7
- Transaction value
- +$107,590
- Accepted by SEC
- 06 Dec 2024, 21:00
- Role
- 10%+ Owner
- Next action
- Open filing details
4
STTK
Shattuck Labs, Inc.
- Report period
- 04 Dec 2024
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 06 Dec 2024, 21:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Augmedix, Inc.
- Report period
- 02 Oct 2024
- Transactions
- 7
- Transaction value
- -$75,402,504
- Accepted by SEC
- 04 Oct 2024, 17:01
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 30 Sep 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 02 Oct 2024, 20:16
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ADCT
ADC Therapeutics SA
- Report period
- 01 Jul 2024
- Transactions
- 2
- Transaction value
- +$2,248,000
- Accepted by SEC
- 03 Jul 2024, 20:00
- Role
- 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 28 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2024, 21:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
STTK
Shattuck Labs, Inc.
- Report period
- 21 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 21 Jun 2024, 19:22
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Augmedix, Inc.
- Report period
- 14 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 18 Jun 2024, 21:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ABSI
Absci Corp
- Report period
- 12 Jun 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 14 Jun 2024, 19:47
- Role
- Director
- Next action
- Open filing details
4
FATE
FATE THERAPEUTICS INC
- Report period
- 07 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 11 Jun 2024, 18:19
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ADCT
ADC Therapeutics SA
- Report period
- 08 May 2024
- Transactions
- 2
- Transaction value
- +$68,669,386
- Accepted by SEC
- 10 May 2024, 16:01
- Role
- 10%+ Owner
- Next action
- Open filing details
4
STTK
Shattuck Labs, Inc.
- Report period
- 28 Mar 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 01 Apr 2024, 21:32
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 28 Mar 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 01 Apr 2024, 21:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
FATE
FATE THERAPEUTICS INC
- Report period
- 21 Mar 2024
- Transactions
- 1
- Transaction value
- +$19,996,366
- Accepted by SEC
- 25 Mar 2024, 21:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Augmedix, Inc.
- Report period
- 15 Mar 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 19 Mar 2024, 21:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 12 Mar 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 14 Mar 2024, 19:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Science 37 Holdings, Inc.
- Report period
- 12 Mar 2024
- Transactions
- 3
- Transaction value
- -$5,848,917
- Accepted by SEC
- 13 Mar 2024, 17:17
- Role
- Former 10% Owner and Director
- Next action
- Open filing details
4
ABSI
Absci Corp
- Report period
- 01 Mar 2024
- Transactions
- 1
- Transaction value
- +$999,999
- Accepted by SEC
- 05 Mar 2024, 21:30
- Role
- Director
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 28 Feb 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 01 Mar 2024, 21:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ADCT
ADC Therapeutics SA
- Report period
- 03 Jan 2024
- Transactions
- 22
- Transaction value
- -$167,175
- Accepted by SEC
- 09 Feb 2024, 21:50
- Role
- 10%+ Owner
- Next action
- Open filing details
3
ADCT
ADC Therapeutics SA
- Report period
- 02 Jan 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 09 Feb 2024, 21:45
- Role
- 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 29 Dec 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 03 Jan 2024, 20:46
- Role
- Director
- Next action
- Open filing details
4
FATE
FATE THERAPEUTICS INC
- Report period
- 26 Dec 2023
- Transactions
- 3
- Transaction value
- +$166,024
- Accepted by SEC
- 28 Dec 2023, 21:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
STTK
Shattuck Labs, Inc.
- Report period
- 21 Dec 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 26 Dec 2023, 21:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Augmedix, Inc.
- Report period
- 15 Dec 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 19 Dec 2023, 21:31
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Augmedix, Inc.
- Report period
- 20 Nov 2023
- Transactions
- 4
- Transaction value
- +$6,000,000
- Accepted by SEC
- 22 Nov 2023, 16:15
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 29 Sep 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 03 Oct 2023, 20:44
- Role
- Director
- Next action
- Open filing details
4
RayzeBio, Inc.
- Report period
- 19 Sep 2023
- Transactions
- 6
- Transaction value
- $0
- Accepted by SEC
- 21 Sep 2023, 21:30
- Role
- 10%+ Owner
- Next action
- Open filing details
3
RayzeBio, Inc.
- Report period
- 14 Sep 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 14 Sep 2023, 21:31
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Augmedix, Inc.
- Report period
- 31 Aug 2023
- Transactions
- 1
- Transaction value
- +$10,000
- Accepted by SEC
- 05 Sep 2023, 21:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Augmedix, Inc.
- Report period
- 13 Jul 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 17 Jul 2023, 18:49
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 29 Jun 2023
- Transactions
- 5
- Transaction value
- $0
- Accepted by SEC
- 03 Jul 2023, 21:45
- Role
- Director
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 26 Jun 2023
- Transactions
- 1
- Transaction value
- +$22,500,000
- Accepted by SEC
- 28 Jun 2023, 21:45
- Role
- Director
- Next action
- Open filing details
4
MedAvail Holdings, Inc.
- Report period
- 16 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 21 Jun 2023, 21:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ABSI
Absci Corp
- Report period
- 14 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 16 Jun 2023, 19:14
- Role
- Director
- Next action
- Open filing details
4
FATE
FATE THERAPEUTICS INC
- Report period
- 06 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 08 Jun 2023, 19:22
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
STTK
Shattuck Labs, Inc.
- Report period
- 26 May 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 31 May 2023, 18:40
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Science 37 Holdings, Inc.
- Report period
- 11 May 2023
- Transactions
- 1
- Transaction value
- +$125,000
- Accepted by SEC
- 15 May 2023, 21:32
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Augmedix, Inc.
- Report period
- 02 May 2023
- Transactions
- 3
- Transaction value
- -$15,000,000
- Accepted by SEC
- 04 May 2023, 21:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
FATE
FATE THERAPEUTICS INC
- Report period
- 20 Apr 2023
- Transactions
- 2
- Transaction value
- +$1,705,829
- Accepted by SEC
- 21 Apr 2023, 21:55
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Augmedix, Inc.
- Report period
- 19 Apr 2023
- Transactions
- 2
- Transaction value
- +$6,999,999
- Accepted by SEC
- 21 Apr 2023, 21:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
FATE
FATE THERAPEUTICS INC
- Report period
- 13 Apr 2023
- Transactions
- 12
- Transaction value
- -$1,611,460
- Accepted by SEC
- 17 Apr 2023, 21:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 04 Apr 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 06 Apr 2023, 21:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 31 Mar 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 04 Apr 2023, 21:32
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MedAvail Holdings, Inc.
- Report period
- 09 Mar 2023
- Transactions
- 2
- Transaction value
- +$24,999,999
- Accepted by SEC
- 13 Mar 2023, 21:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 30 Dec 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 04 Jan 2023, 20:33
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4/A
ZYME
Zymeworks Inc.
- Report period
- 13 Oct 2022
- Transactions
- 1
- Transaction value
- +$153,435
- Accepted by SEC
- 18 Oct 2022, 06:07
- Role
- 10%+ Owner
- Next action
- Open filing details
3
ZYME
Zymeworks Inc.
- Report period
- 13 Oct 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 17 Oct 2022, 21:46
- Role
- 10%+ Owner
- Next action
- Open filing details
3
ZYME
Zymeworks Inc.
- Report period
- 13 Oct 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 17 Oct 2022, 21:45
- Role
- 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 03 Oct 2022
- Transactions
- 6
- Transaction value
- $0
- Accepted by SEC
- 05 Oct 2022, 17:01
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 30 Sep 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 04 Oct 2022, 22:01
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MedAvail Holdings, Inc.
- Report period
- 01 Jul 2022
- Transactions
- 4
- Transaction value
- +$18,116,562
- Accepted by SEC
- 06 Jul 2022, 17:17
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 30 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 05 Jul 2022, 21:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Science 37 Holdings, Inc.
- Report period
- 13 Jun 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 15 Jun 2022, 18:02
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
FATE
FATE THERAPEUTICS INC
- Report period
- 09 Jun 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2022, 21:31
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
STTK
Shattuck Labs, Inc.
- Report period
- 08 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 10 Jun 2022, 21:32
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ABSI
Absci Corp
- Report period
- 08 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 10 Jun 2022, 21:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Science 37 Holdings, Inc.
- Report period
- 23 May 2022
- Transactions
- 1
- Transaction value
- +$124,998
- Accepted by SEC
- 25 May 2022, 21:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MedAvail Holdings, Inc.
- Report period
- 04 Apr 2022
- Transactions
- 2
- Transaction value
- +$14,999,999
- Accepted by SEC
- 06 Apr 2022, 21:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 31 Mar 2022
- Transactions
- 2
- Transaction value
- +$59,999,985
- Accepted by SEC
- 04 Apr 2022, 21:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 12 Mar 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 15 Mar 2022, 21:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 31 Dec 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 04 Jan 2022, 20:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TRDA
Entrada Therapeutics, Inc.
- Report period
- 02 Nov 2021
- Transactions
- 3
- Transaction value
- +$20,000,000
- Accepted by SEC
- 04 Nov 2021, 21:00
- Role
- 10%+ Owner
- Next action
- Open filing details
4/A
Augmedix, Inc.
- Report period
- 28 Oct 2021
- Transactions
- 1
- Transaction value
- +$6,500,000
- Accepted by SEC
- 21 Apr 2023, 21:53
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
TRDA
Entrada Therapeutics, Inc.
- Report period
- 28 Oct 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 28 Oct 2021, 21:01
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Science 37 Holdings, Inc.
- Report period
- 07 Oct 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 12 Oct 2021, 21:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4/A
Science 37 Holdings, Inc.
- Report period
- 06 Oct 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 18 Oct 2021, 16:06
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
Science 37 Holdings, Inc.
- Report period
- 06 Oct 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 08 Oct 2021, 21:01
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 30 Sep 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 04 Oct 2021, 21:01
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IVVD
Adagio Therapeutics, Inc.
- Report period
- 10 Aug 2021
- Transactions
- 3
- Transaction value
- +$24,990,000
- Accepted by SEC
- 12 Aug 2021, 21:01
- Role
- 10%+ Owner
- Next action
- Open filing details
3
IVVD
Adagio Therapeutics, Inc.
- Report period
- 05 Aug 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 05 Aug 2021, 21:07
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ABSI
Absci Corp
- Report period
- 26 Jul 2021
- Transactions
- 5
- Transaction value
- +$5,000,000
- Accepted by SEC
- 28 Jul 2021, 21:01
- Role
- Director
- Next action
- Open filing details
3
ABSI
Absci Corp
- Report period
- 21 Jul 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 21 Jul 2021, 21:31
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 30 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2021, 16:32
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
VERV
Verve Therapeutics, Inc.
- Report period
- 21 Jun 2021
- Transactions
- 3
- Transaction value
- +$19,950,000
- Accepted by SEC
- 23 Jun 2021, 16:16
- Role
- 10%+ Owner
- Next action
- Open filing details
4
STTK
Shattuck Labs, Inc.
- Report period
- 19 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 22 Jun 2021, 20:09
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
VERV
Verve Therapeutics, Inc.
- Report period
- 16 Jun 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 16 Jun 2021, 21:00
- Role
- 10%+ Owner
- Next action
- Open filing details
4
FATE
FATE THERAPEUTICS INC
- Report period
- 02 Jun 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 04 Jun 2021, 16:07
- Role
- Director, 10%+ Owner
- Next action
- Open filing details